Table 3.
IBS‐QoL total scores and scores in the eight domains of the scale in placebo and FMT‐treated patients
| Time | Group | Total score | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | Placebo | 115.2 ± 20.6 | 26.6 ± 6.4 | 22.9 ± 5.8 | 11.7 ± 2.8 | 10.5 ± 2.5 | 6.8 ± 2.8 | 14. ± 3.3 | 7.5 ± 1.9 | 11.1 ± 2.7 |
| 30‐g FMT | 109.8 ± 22.3 | 26.3 ± 6.8 | 19.8 ± 5.6 | 11.1 ± 3.4 | 10.4 ± 2.7 | 5.8 ± 2.7 | 13.7 ± 3.4 | 7.6 ± 1.9 | 10.9 ± 2.4 | |
| 60‐g FMT | 113.1 ± 20.9 | 27.4 ± 6.5 | 21.0 ± 4.7 | 11.7 ± 2.6 | 10.6 ± 2.5 | 6.6 ± 2.8 | 14.0 ± 3.3 | 7.6 ± 1.7 | 10.9 ± 2.6 | |
| 1 month | Placebo | 121.9 ± 28.3 | 28.9 ± 7.4 | 23.0 ± 5.7 | 12.7 ± 4.5 | 12.2 ± 2.6* | 8.0 ± 3.0 | 14.7 ± 3.7 | 7.3 ± 2.4 | 11.2 ± 3.1 |
| 30‐g FMT | 122.8 ± 23.3** | 29.9 ± 6.8** | 21.9 ± 4.8* | 13.3 ± 3.8** | 11.9 ± 2.3** | 7.1 ± 2.9* | 16.0 ± 3.0*** | 7.9 ± 1.7 | 11.6 ± 2.3 | |
| 60‐g FMT | 126.1 ± 23.6** | 30.9 ± 6.4** | 22.7 ± 4.8* | 13.8 ± 3.3** | 12.0 ± 2.4* | 8.4 ± 3.2*** | 15.0 ± 3.7 | 8.2 ± 2.0 | 11.5 ± 2.5 |
IBS‐QoL domains: 1, dysphoria; 2, interference with daily activities; 3, body image; 4, health worries; 5, food avoidance; 6, social reaction; 7, sexual function; and 8, impact on relations.
p<0.05;
p < 0.01;
p < 0.001.